[Federal Register Volume 88, Number 100 (Wednesday, May 24, 2023)]
[Notices]
[Page 33614]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-10979]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. FDA-2020-E-2361; FDA-2020-E-2362; and FDA-2020-E-2363]


Determination of Regulatory Review Period for Purposes of Patent 
Extension; ENSPRYNG; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or the Agency) is 
correcting a notice that appeared in the Federal Register of July 13, 
2022. The document determined the regulatory review period for 
ENSPRYNG. After review of a timely request for reconsideration by the 
applicant of the calculation of the applicable regulatory review period 
of the biologic product ENSPRYNG in that notice, FDA has determined 
that a revision of the supplementary information section is warranted. 
This notice corrects the applicable regulatory review period language.

FOR FURTHER INFORMATION CONTACT: Beverly Friedman, Office of Regulatory 
Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 
51, Rm. 6250, Silver Spring, MD 20993, 301-796-3600.

SUPPLEMENTARY INFORMATION: In the Federal Register of July 13, 2022 (87 
FR 41724), on page 41725, in the second column, under ``II. 
Determination of Regulatory Review Period,'' the first two sentences 
should be corrected to read as follows: ``FDA has determined that the 
applicable regulatory review period for ENSPRYNG is 2,494 days. Of this 
time, 2,128 days occurred during the testing phase of the regulatory 
review period, while 366 days occurred during the approval phase.''

    Dated: May 18, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-10979 Filed 5-23-23; 8:45 am]
BILLING CODE 4164-01-P


